The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Outcomes of delaying CAR-T infusion after lymphodepleting chemotherapy in patients with LBCL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study investigating the effect of delaying CAR-T infusion after completion of lymphodepleting chemotherapy on the outcomes of patients with large B-cell lymphoma (LBCL). Dr Strati explains that the most common reason for delaying CAR-T infusion is infections. The study found that patients who had delayed infusion had a shorter progression-free survival (PFS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Hutchinson MediPharma: Consultancy; ADC Therapeutics: Consultancy, Research Funding; TG Therapeutics: Consultancy; Kite Gilead: Consultancy; Astrazeneca Acerta: Research Funding; ALX Oncology: Research Funding; Sobi: Research Funding; Roche Genentech: Consultancy.
